Annual Sales of Nexavar reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Annual Sales of Nexavar(R) reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Sales in first-half 2020 totaled €442 million ($495 million), 1.8 percent more than in the same period for 2019. The cancer drug Nexavar had 2019 sales of €706 million ($790 million), down 0.8 percent versus 2018. Nexavar is used to treat liver, kidney and thyroid cancer. According to a Bayer report, the company earned more than $700 million from sales of the drug worldwide in fiscal year 2020. How many physicians were reached by Nexavar through reportable promotional activity in 2020 and how does this compare to its peer set in the Hepatocellular Carcinoma, Renal Cancer, and Thyroid Cancer markets? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity? How does Bayer's depth of … Nexavar is used to treat liver, kidney, and thyroid cancer. According to a Bayer report, it sold more than $750 million worth of Nexavar worldwide in fiscal year 2020. Otezla* generated $617 million of sales in the fourth quarter of 2020, and $2.2 billion for the full year. Bayer's leading sales product during full-year 2020 and first-half 2021 was the oral anticoagulant Xarelto. The blood thinner received approval in China during January 2021 for treating venous thromboembolism, becoming the first oral Factor Xa inhibitor to be licensed for the treatment and prevention of recurrent VTE in children. FOR IMMEDIATE RELEASE TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results – Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 – – 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 – – ANNOVERA® net product revenue increased 42% for 4Q20 compared to 3Q20 – – Financing Agreement amended to update … There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the sorafenib tosylate profile page. DrugPatentWatch ® Litigation and Generic Entry Outlook for Nexavar A generic version of Nexavar was approved as sorafenib tosylate by MYLAN on September 10 th, 2020. Start … NEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) Annual Sales of Sorafenib – Nexavar reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. FDA approval history for Nexavar (sorafenib) used to treat Renal Cell Carcinoma (RCC), Hepatocellular Carcinoma, Thyroid Cancer. Supplied by Bayer Pharmaceuticals Corporation Annual Sales of Nexavar, Bay 43-9006, Sorafenib Tosylate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Nexavar has been firmly established as the standard of care in advanced HCC since gaining approval in the US in 2007. However, it has steadily lost market share after the introduction of generics in 2020 (US), 2021 (EU), and 2022 (Japan). Additionally, Nexavar has faced strong competition from the combination of Tecentriq + bevacizumab, which was the first regimen to demonstrate both superior … Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. 3.3.2 Sales of Sorafenib in China 4 Sales Price of Sorafenib of Different Companies in China, 2020-2021 4.1 Bayer AG (Nexavar) 4.2 Jiangxi Shanxiang Pharmaceutical Co., Ltd. (Ligesitai) While the global sales rankings of Big Pharma's superstar drugs naturally feature the biggest names in the business, new meds often pop up or old drugs exit the scene. And the moves within the … Wondering when a generic version of Nexavar will be available? Get details on FDA approval status, generic manufacturers, and patent expirations. Overview Nexavar (sorafenib) – Drug Insight and Market Forecast – 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Nexavar (sorafenib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is … Onyx and Bayer have said Nexavar could garner future annual sales of well above $1 billion if it were eventually approved for liver cancer and other tumors, including those of the lung and breast. It said sales in its pharmaceutical segment are expected to rise 1%, with growth "substantially skewed" towards the second half. Bayer estimates Xarelto will see a decline in the mid-single digits driven by ongoing pricing pressure, while combined sales for Nubeqa and Kerendia are projected to exceed €1 billion this year. Under the license, Natco must pay 6% in royalties to Bayer from the sale of the drug, which is needed by about 8,800 cancer patients in India today. Natco said its version of generic Nexavar would cost Indian patients $175 a month, instead of about $5,600 which Bayer markets sorefinib as Nexavar under a 2008-2020 patent. NEXAVAR is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma ( 1.1 ) Advanced renal cell carcinoma ( 1.2 ) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) Nexavar is a drug owned by Bayer Healthcare Pharmaceuticals Inc. It is protected by 8 US drug patents filed from 2013 to 2017. Out of these, 2 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 10, 2028. Details of Nexavar's patents and their expiration are given in the table below. Nexavar API market analysis, production, capacity, average price, market share, top market trends, import vs export Treat Nexavar as legacy oncology paying manufacturing overhead and modest residual royalties. Not investment advice. Sorafenib is a mature molecule in structural decline. Peak Nexavar sales reached approximately $1.2 to $1.4B annually in the 2012 to 2014 window and have eroded steadily since generic entry around 2020. Works to improve our capabilities for early threat detection and monitoring of health care nexavar sales. CR allows faster receipt of data, which speeds case investigations, outbreak definition, and exposure identification, thus minimizing the burden on our healthcare partners. The global kidney cancer drugs market is expected to decline from $3.3 billion in 2020 to $3.29 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%. The safety of NEXAVAR was evaluated in DECISION in 416 patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) treatment randomized to receive 400 mg twice daily NEXAVAR (n=207) or matching placebo (n=209) until disease progression or intolerable toxicity in a … The RLD upon which you have based your ANDA, Bayer's Nexavar Tablets, 200 mg, is also subject to a period of exclusivity. As noted in the Orange Book, the ODE-56 exclusivity is scheduled to expire on November 22, 2020. You have provided a copy of a letter from Bayer's counsel, which notes that Bayer waives the unexpired ODE-56 exclusivity period with respect to Mylan's ANDA 207012, effective … Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Sales forecast by class of drugs for hepatocellular carcinoma Kinase inhibitors such as Bayer's Nexavar (sorafenib) and Eisai's Lenvima (lenvatinib), have dominated the hepatocellular carcinoma (HCC) market for more than a decade and until recently were the standard of care (SOC) in first-line advanced HCC. The safety of NEXAVAR was evaluated in DECISION in 416 patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) treatment randomized to receive 400 mg twice daily NEXAVAR (n=207) or matching placebo (n=209) until disease progression or intolerable toxicity in a … NEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 2010-2020 PATENT EXPIRY DATES 1/3 The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide. How have Nexavar sales trended since launch and what is the current market size? Direct answer: Nexavar is in a mature, declining-to-flat late lifecycle in most OECD markets, with residual volume supported by established clinical utility, slower uptake in some markets due to tendering and reimbursement structures, and ongoing use where newer … 3 DOSAGE FORMS AND STRENGTHS Tablets containing sorafenib tosylate (274 mg) equivalent to 200 mg of sorafenib. NEXAVAR tablets are round, biconvex, red film-coated tablets, debossed with the "Bayer cross" on one side and "200" on the other side.